

=====

Sequence Listing was accepted with existing errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Wed May 23 12:25:26 EDT 2007

=====

Application No: 10580164 Version No: 1.1

Input Set:

Output Set:

Started: 2007-05-23 12:25:14.656

Finished: 2007-05-23 12:25:14.731

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 75 ms

Total Warnings: 0

Total Errors: 0

No. of SeqIDs Defined: 4

Actual SeqID Count: 4

# SEQUENCE LISTING

<110> Christie, Mark Ian  
Mead, Richard James  
Robinson, Martyn Kim  
Rapecki, Stephen Edward

<120> METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY INHIBITING  
IL-17 ACTIVITY

<130> CELL-0316

<140> 10/580,164  
<141> 2006-05-18

<150> PCT/GB2004/004850  
<151> 2004-11-16

<150> GB 0417115.3  
<151> 2004-07-30

<150> GB 0327181.4  
<151> 2003-11-21

<160> 4

<170> PatentIn version 3.3

<210> 1  
<211> 103  
<212> PRT  
<213> Homo sapiens

<400> 1

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys  
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr  
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser  
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser  
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr  
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys  
85 90 95

Lys Val Glu Pro Lys Ser Cys  
100

<210> 2  
<211> 108  
<212> PRT  
<213> Homo sapiens

<400> 2

Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp  
1 5 10 15

Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn  
20 25 30

Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu  
35 40 45

Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp  
50 55 60

Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr  
65 70 75 80

Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser  
85 90 95

Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys  
100 105

<210> 3  
<211> 101  
<212> PRT  
<213> Mus musculus

<400> 3

Lys Thr Thr Pro Pro Ser Val Tyr Pro Leu Ala Pro Gly Ser Ala Ala  
1 5 10 15

Gln Thr Asn Ser Met Val Thr Leu Gly Cys Leu Val Lys Gly Tyr Phe  
20 25 30

Pro Glu Pro Val Thr Val Thr Trp Asn Ser Gly Ser Leu Ser Ser Gly

35

40

45

Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu Ser  
50 55 60

Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val Thr  
65 70 75 80

Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys Ile  
85 90 95

Val Pro Arg Asp Cys  
100

&lt;210&gt; 4

&lt;211&gt; 105

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 4

Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu  
1 5 10 15

Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr Pro  
20 25 30

Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn  
35 40 45

Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr  
50 55 60

Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg His  
65 70 75 80

Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro Ile  
85 90 95

Val Lys Ser Phe Asn Arg Gly Glu Cys  
100 105